The drug is decades old, and its intranasal option was first approved in 2015. The committee members said their greenlight votes were based on access barriers, the thousands of Americans who die every year from opioids and the low risk of errors.
The drugmaker Emergent BioSolutions filed the nonprescription application, according to the committee’s briefing document.
“It’s a huge public health benefit and it’s way overdue,” one panelist said.
The FDA is scheduled to make the final vote by March 29.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
